Quanome Dilutes 16% to Buy 5% of Pre-Commercial QAI Labs
QNME sits 50% above its 52-week low of $0.25.
Summary
Quanome will issue 6,541,236 new shares — about 19% of its pre-issuance count and 15.97% post-issuance — for roughly 5% of early-stage QAI Labs, under a stock purchase agreement dated November 4, 2026. The parties put a negotiated value of $5.0M on the consideration, implying an approximately $100M equity value for QAI, which is pre-commercial and has no revenue. That is a heavy dilution price for a minority stake in a company whose NOVA-3 candidates still need lab validation, clinical development and regulatory approval. The deal follows the $9.75M Maxim ATM at $0.474 and the going-concern warning in the September 10-K, so the equity is being spent rather than raised in cash. Closing is subject to customary conditions, including regulatory consents, with a December 31, 2026 termination deadline, so the stake and the share issuance are not yet final.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The stock purchase agreement is dated November 4, 2026, with closing conditions including regulatory consents and a December 31, 2026 termination deadline.
At the time of this announcement, QNME was trading at $0.38 on NASDAQ in the Technology sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $0.25 to $1.40. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.